# Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

> **NCT07104812** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 15 (estimated)

## Conditions studied

- Mild Autonomous Cortisol Secretion
- Autonomous Cortisol Secretion (ACS)

## Interventions

- **DRUG:** Osilodrostat 1 MG

## Key facts

- **NCT ID:** NCT07104812
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-14
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07104812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07104812, "Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07104812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*